A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
Phase 2
Completed
NCT06454630
| Condition | Venous Thromboembolism |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Regeneron Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 179 participants |
|---|
| Interventions | REGN7508, Enoxaparin |
|---|
| Start date | Jun 27, 2024 |
|---|
| Completion date | Nov 19, 2024 |
|---|
| Results posted | Mar 2, 2026 |
|---|
Summary
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement (TKR) surgery. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related diseases after unilateral total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)
Through day 12 · percentage of participants
| REGN7508 | 7.1 percentage of participants |
|---|
| Enoxaparin | 17.2 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.